By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.
Wyeth v. Osmotica Pharmaceutical Corp.
7:07-cv-00067; filed April 20, 2007 in the Eastern District of North Carolina
Infringement of U.S. Patent Nos. 6,403,120 ("Extended Release Formulation of Venlafaxine Hydrochloride," issued June 11, 2002) and 6,419,958 (same title, issued July 16, 2002) based on Osmotica's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Wyeth's Effexor® XR (venlafaxine hydrochloride, used to treat depression). View the complaint here.
Comments